The latest price target for Chemours (NYSE:CC) was reported by Morgan Stanley on January 13, 2025. The analyst firm set a price target for $22.00 expecting CC to rise to within 12 months (a possible 13.40% upside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for Chemours (NYSE:CC) was provided by Morgan Stanley, and Chemours maintained their equal-weight rating.

The last upgrade for The Chemours Co happened on July 9, 2024 when UBS raised their price target to $30. UBS previously had a neutral for The Chemours Co.

The last downgrade for The Chemours Co happened on March 5, 2024 when UBS changed their price target from $37 to $21 for The Chemours Co.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Chemours, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Chemours was filed on January 13, 2025 so you should expect the next rating to be made available sometime around January 13, 2026.

While ratings are subjective and will change, the latest Chemours (CC) rating was a maintained with a price target of $25.00 to $22.00. The current price Chemours (CC) is trading at is $19.40, which is out of the analyst’s predicted range.